Connecting patients with
professional test results
from the LumiraDx Platform
Uncompromised on-site testing with the LumiraDx Platform provides rapid and accurate COVID-19 testing. Adding the LumiraDx Engage App simplifies sample tracking to improve the pre-test process and conveniently delivers results to an individual’s inbox.
Rapidly identify potentially contagious spreaders on the spot, reducing the risk of a local outbreak & the potential impact on your events, schools, workplace or operations, helping to build customer, guest and staff confidence.
Individuals can register off site allowing a streamlined testing process and reducing on site interactions
Multiple layer ID verification and age consent capabilities
Lab comparable results within 12 minutes on the LumiraDx Platform facilitating rapid turnaround of results
Test results will be sent securely and directly to the account holders registered email address
Not all products are available in all countries and regions. Please check with your local LumiraDx sales representative or distributor for availability in specific markets.
LumiraDx SARS-CoV-2 Ag Test has not been cleared or approved by FDA. The LumiraDx SARS-CoV-2 Ag test has been authorized by FDA under an EUA only for the detection of SARS-CoV-2 nucleocapsid protein. The test has not been authorized for use to detect any other viruses or pathogens. The test is authorized in the United States for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Supporting healthier lives, for individuals, communities and wider society
Enabling responsive, personal relationships between patients and care teams.
Controlling and reducing costs to help ease pressure on healthcare budgets.